Phase 2 Study of Axitinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Axitinib (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 04 Jan 2018 Results assessing safety and efficacy published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 24 Apr 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.